Article

Linezolid Acts as a Selective Inhibitor of the JAK2 <sup>V617F</sup> Mutation

2026-06-03

Abstract excerpt

<h4>ABSTRACT</h4> The JAK2 V617F (JAK2 VF ) driver mutation is found in 95% of patients with polycythemia vera (PV), a progressive myeloproliferative neoplasm. Current treatments suppress excessive hematopoiesis but lack specificity for targeting JAK2 VF cells, are unable to deplete mutant stem/progenitor cells and ultimately result in drug resistance. We discovered that the FDA-approved antibiotic, linezolid...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6a7210b1-5f04-5c65-bfd4-9630b36c1df2
DOI: 10.64898/2026.05.31.729063

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Linezolid Acts as a Selective Inhibitor of the JAK2 <sup>V617F</sup> MutationDOI 10.64898/2026.05.31.729063Read

Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617FSemantic proximity Read

Erlotinib Effectively Inhibits JAK2V617F Activity and Polycythemia Vera Cell GrowthSemantic proximity Read

Efficacy of vorinostat in a murine model of polycythemia veraSemantic proximity Read

Genome editing for treatment of <i>JAK2</i> V617F-driven myeloproliferative neoplasmsSemantic proximity Read

Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805.Semantic proximity Read

Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia.Semantic proximity Read

Discovery of 5-Chloro-<i>N</i><sup>2</sup>-[(1<i>S</i>)-1-(5-fluoropyrimidin-2-yl)ethyl]-<i>N</i><sup>4</sup>-(5-methyl-1<i>H</i>-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a Novel Inhibitor of the Jak/Stat PathwaySemantic proximity Read

Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasmsSemantic proximity Read

Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation.Semantic proximity Read

R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm.Semantic proximity Read

Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.Semantic proximity Read

Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia.Semantic proximity Read